Clinical trial · Observational
Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
Construction of a Standardized Benchmark Evaluation System for Intelligent Breast Ultrasound Image Interpretation and Systematic Performance Assessment of Multimodal Artificial Intelligence Models Based on ACR BI-RADS v2025 Criteria
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This single-center, retrospective, observational study aims to construct a standardized benchmark evaluation system for intelligent breast ultrasound image interpretation and to systematically assess the diagnostic performance of current mainstream multimodal artificial intelligence (AI) models. De-identified B-mode breast ultrasound images with confirmed pathological diagnoses will be retrospectively collected from the institutional archive (2018-2025) and supplemented with images from published open-access datasets. Expert radiologists with varying experience levels will independently annotate all images according to the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) v2025 criteria, including glandular tissue composition, lesion characterization (mass vs. non-mass lesion), morphological descriptors, and final BI-RADS classification. Baseline deep learning models (CNN-based ResNet-50 and Transformer-based USFM) will be trained to establish performance baselines and to stratify cases by diagnostic difficulty through cross-architecture consensus. Multiple multimodal large language models (MLLMs), including both general-purpose and medical-domain models, will then be evaluated via standardized API calls using BI-RADS-guided chain-of-thought prompts at temperature 0 for reproducibility. Primary endpoints include BI-RADS classification accuracy and diagnostic AUC for benign-malignant differentiation. Model robustness and safety will be assessed through out-of-distribution rejection testing, temperature-stability experiments, and thinking-mode ablation studies. This study adheres to the FLAIR and TRIPOD-LLM reporting guidelines.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Diseases | — | UNRESOLVED | — |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Ultrasonography | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multimodal AI Model Diagnostic Evaluation | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Normal Breast
- description
- Breast ultrasound images showing normal glandular tissue across different tissue composition types, with no focal lesions identified. Confirmed by senior radiologist review.
- interventionNames
- Diagnostic Test: Multimodal AI Model Diagnostic Evaluation
- label
- Benign Lesion
- description
- Breast ultrasound images containing pathologically confirmed benign lesions (BI-RADS 2-4B), including fibroadenoma, cyst, lipoma, sclerosing adenosis, intraductal papilloma, and selected non-mass lesions (NML).
- interventionNames
- Diagnostic Test: Multimodal AI Model Diagnostic Evaluation
- label
- Malignant Lesion
- description
- Breast ultrasound images containing pathologically confirmed malignant lesions (BI-RADS 3-5), including invasive ductal carcinoma, invasive lobular carcinoma, mucinous carcinoma, and selected non-mass lesions (NML).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * B-mode breast ultrasound grayscale images from the institutional PACS database or from published open-access breast ultrasound datasets with documented original institutional ethics approval * Image quality adequate for clinical diagnosis with clear visualization of the region of interest * Pathological diagnosis confirmed (for benign and malignant lesion groups), or normal breast status confirmed by a senior radiologist with \>15 years of breast ultrasound experience (for the normal group) * Complete de-identification with removal of all personally identifiable information Exclusion Criteria: * Severely degraded image quality precluding meaningful BI-RADS assessment * Duplicate images from the same patient (only the most representative image retained per lesion) * Images with residual personally identifiable information after de-identification processing * Cases with ambiguous, disputed, or unavailable pathological results * Non-B-mode ultrasound images, including elastography, contrast-enhanced ultrasound, and Doppler imaging
References
Publications (12)
- BACKGROUNDBi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH, Tamimi RM, Tempany CM, Swanton C, Hoffmann U, Schwartz LH, Gillies RJ, Huang RY, Aerts HJWL. Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 2019 Mar;69(2):127-157. doi: 10.3322/caac.21552. Epub 2019 Feb 5. PMID 30720861
- BACKGROUNDBhayana R, Krishna S, Bleakney RR. Performance of ChatGPT on a Radiology Board-style Examination: Insights into Current Strengths and Limitations. Radiology. 2023 Jun;307(5):e230582. doi: 10.1148/radiol.230582. Epub 2023 May 16. PMID 37191485
- BACKGROUNDClusmann J, Kolbinger FR, Muti HS, Carrero ZI, Eckardt JN, Laleh NG, Loffler CML, Schwarzkopf SC, Unger M, Veldhuizen GP, Wagner SJ, Kather JN. The future landscape of large language models in medicine. Commun Med (Lond). 2023 Oct 10;3(1):141. doi: 10.1038/s43856-023-00370-1. PMID 37816837
- BACKGROUNDSeyyed-Kalantari L, Zhang H, McDermott MBA, Chen IY, Ghassemi M. Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations. Nat Med. 2021 Dec;27(12):2176-2182. doi: 10.1038/s41591-021-01595-0. Epub 2021 Dec 10. PMID 34893776
- BACKGROUNDMoor M, Banerjee O, Abad ZSH, Krumholz HM, Leskovec J, Topol EJ, Rajpurkar P. Foundation models for generalist medical artificial intelligence. Nature. 2023 Apr;616(7956):259-265. doi: 10.1038/s41586-023-05881-4. Epub 2023 Apr 12. PMID 37045921
- BACKGROUNDSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID 33538338
- Benary M, Wang XD, Schmidt M, Soll D, Hilfenhaus G, Nassir M, Sigler C, Knodler M, Keller U, Beule D, Keilholz U, Leser U, Rieke DT. Leveraging Large Language Models for Decision Support in Personalized Oncology. JAMA Netw Open. 2023 Nov 1;6(11):e2343689. doi: 10.1001/jamanetworkopen.2023.43689.